

### REMARKS

Method-of-use Claims 37-47 are the only claims now pending in this application. Method-of-use Claims 37-47 define a method for treating renal failure by use of a renin-inhibiting compound defined in the chemical recitations therein.

\* \* \*

Method-of-use Claims 37-47 stand rejected in an earlier-issued Office Action (Paper No. 7, dated 13 September 2002) under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-11 of U.S. Patent No. 6,342,624.

U.S. Patent 6,342,624 and the subject Application are co-owned by Applicants' Assignee.

Applicants attempted to overcome this rejection by introduction of a Terminal Disclaimer, in compliance with 37 C.F.R. §1.321(b), for the claims of the subject Application over the term of cited U.S. Patent 6,342,624.


Due to inadvertence, Applicants had a typographical error in said Terminal Disclaimer (filed on 13 March 2003) at fifth line of first page in the recitation of the Serial Number of the present application.

Attached hereto is a "substitute Terminal Disclaimer"  
identical to the earlier-submitted Terminal Disclaimer but with  
corrected Serial Number for the present application.

\* \* \*

In view of foregoing Remarks, Claims 37-47 should be in  
condition for allowance.

Respectfully submitted,



J. Timothy Keane  
Attorney for Applicants  
Registration No. 27,808  
314-274-9090

Pharmacia Corporation  
Global Patent Department  
P.O. Box 1027  
Chesterfield, MO 63006

Attachments

Substitute Terminal Disclaimer